Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Free Cash Flow (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Free Cash Flow data on record, last reported at -$33.2 million in Q4 2025.

  • For Q4 2025, Free Cash Flow fell 3.11% year-over-year to -$33.2 million; the TTM value through Dec 2025 reached -$129.6 million, down 189.73%, while the annual FY2025 figure was -$129.6 million, 189.73% down from the prior year.
  • Free Cash Flow reached -$33.2 million in Q4 2025 per TRDA's latest filing, down from -$28.3 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $201.7 million in Q1 2023 and bottomed at -$39.7 million in Q1 2025.
  • Average Free Cash Flow over 4 years is -$8.0 million, with a median of -$26.1 million recorded in 2023.
  • Peak YoY movement for Free Cash Flow: skyrocketed 1043.46% in 2023, then plummeted 7831.41% in 2024.
  • A 4-year view of Free Cash Flow shows it stood at -$25.2 million in 2022, then surged by 101.65% to $417000.0 in 2023, then tumbled by 7831.41% to -$32.2 million in 2024, then dropped by 3.11% to -$33.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$33.2 million in Q4 2025, -$28.3 million in Q3 2025, and -$28.3 million in Q2 2025.